GU Cancers Symposium

Part of Shore’s recommendations include 15 to 30 minutes of exercise daily, consisting of both a cardio component and some level of cross resistance for muscle development.

"These findings may directly inform clinical care, such as providing diet recommendations for managing health, and potentially offer other positive health benefits for preventing numerous chronic diseases,” said Bradley Alexander McGregor, MD.

"We also saw in the high-risk group that patients who identified as Black were much more likely to not receive treatment than their White counterparts," says Madison Novosel, BA.

“What we saw in phase 3 studies and what we've seen in earlier studies—early phase 1/2 studies—is really a paucity of cognitive impairment and a paucity of depression with darolutamide that we've seen across the class of androgen receptor signaling inhibitors,” says Neal Shore, MD.

"The Medicaid and uninsured patients had significantly lower odds of getting treatment than those who [have] private insurance," says Madison Novosel, BA.

Laura Bukavina, MD, and Kyle Rose, MD, discuss some of the notable abstracts from the 2023 ASCO GU conference.

Neal Shore, MD, discusses results from the open-label rollover study from the phase 3 ARAMIS trial, which he presented at the 2023 Genitourinary Cancers Symposium.

“The field of germline testing for prostate cancer has expanded significantly; it's really become central in terms of thinking about treatment for men with metastatic prostate cancer,” says Veda Giri, MD.

The secondary analysis Hussain presented at the GU Symposium showed that the risk of death was reduced by 32% across all volume and subgroups in men with mHSPC treated with the darolutamide-based triplet regimen.

"In our lab, we found that when you gave it to the mice model of bladder cancer, the tumors go away, and they're infiltrated with immune cells," says Joshua J. Meeks, MD, PhD.

"While the data are still early, EG-70's safety profile and efficacy are well on their way towards establishing a new benchmark for monotherapy treatment of high-risk NMIBC with BCG-unresponsive carcinoma in situ,” said lead study author Gary Steinberg MD.

"The model that we developed was able to behave as accurately as clinical models that were previously validated," says Nour Abdallah, MD.

"Darolutamide achieved the primary endpoint. Easily 100% of the patients had a PSA decrease above 90%," says Bertrand F. Tombal, MD, PhD.

“We need to pursue further education in the field and reach out to every community practice and make them understand that we do now have the guidelines in place, the reimbursement in place, and cost is going down for actually adding system-wide germline and somatic testing for these patients,” says Eleni Efstathiou, MD, PhD.

"The majority of my talk focused on describing differences in cancer-specific [survival] as well as overall survival," says Christine Ibilibor, MD.

The toxicity profile was consistent with the first interim analysis of the phase 3 MAGNITUDE study with no new safety signals observed.

"These numbers compared favorably to [CheckMate-214], indicating the value of having a regimen where there was a defined treatment endpoint," says Michael B. Atkins, MD.

Patients with renal cell carcinoma who had progressive disease or stable disease after frontline nivolumab had a substantial treatment-free survival period following salvage immunotherapy with nivolumab plus ipilimumab.

The updated data sustained the previous radiographic progression-free survival benefit observed with the niraparib combination and showed that the combination also met several secondary end points.

"[This is] a group of patients that there are few treatments available for, and we're excited about the data," says Daniel P. Petrylak, MD.

"Looking at the effect of the darolutamide on docetaxel, we didn't see much of a difference in dose reduction, dose modification, or dose hold for docetaxel, telling you that darolutamide didn't really affect the dosing of docetaxel," says Arash Rezazadah Kalebasty, MD.

Baseline findings showed that patients treated with first-line platinum-based chemotherapy prior to avelumab maintenance experienced a complete response rate of 13% and a partial response rate of 68% to chemotherapy.

The real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.

"We're trying to understand where these new therapeutic agents might fit into our paradigms of care," says John L. Gore, MD, MS.

"This trial did not require a biomarker for entry in, so patients were treated with combination therapy or standard care, which would have been the abiraterone alone, to see if there was a benefit," says Michael S. Cookson, MD, MMHC.

Median progression-free survival in the intent-to-treat population by blinded independent central review was 16.6 months (95% CI, 12.8-19.8) with nivolumab plus cabozantinib vs 8.4 months (95% CI, 7.0-9.7) with sunitinib (HR, 0.58; 95% CI, 0.48-0.71).

The median progression-free survival (PFS) was 16.9 months (95% CI, 11.5-not estimable) with cabozantinib vs 11.3 months (95% CI, 7.7-14.0) with placebo in the PFS intention-to-treat population.

Data from the 3-month analysis showed that the cabozantinib elicited an objective response rate of 29.5% (95% CI, 20.3%-40.2%) in the total population (n = 88), which comprised a complete response rate of 1.2% and a partial response rate of 30.5%.

At a median follow-up of 13.4 months, 336 (75%) OS events occurred with atezolizumab plus platinum and gemcitabine and 310 (78%) occurred with placebo plus platinum and gemcitabine.

An exploratory analysis of the IMvigor130 study failed to show an improvement in overall survival with atezolizumab, compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.